Literature DB >> 29345970

The Prevalence and Significance of Staphylococcus aureus in Patients with Non-Cystic Fibrosis Bronchiectasis.

Mark L Metersky1, Timothy R Aksamit2, Alan Barker3, Radmila Choate4, Charles L Daley5, Leigh A Daniels6, Angela DiMango7, Edward Eden8, David Griffith9, Margaret Johnson10, Michael Knowles11, Anne E O'Donnell12, Kenneth Olivier13, Matthias Salathe14, Byron Thomashow15, Gregory Tino16, Gerard Turino8, Kevin L Winthrop3, David Mannino4.   

Abstract

RATIONALE: Staphylococcus aureus is commonly cultured from the sputum of patients with bronchiectasis; however, little is known about the prevalence of the organism in these patients, the characteristics of patients who have grown the organism, or its implications.
OBJECTIVES: Determine the relationship between S. aureus and pulmonary function, frequency of exacerbations, and frequency of hospitalization in patients with bronchiectasis
Methods: The Bronchiectasis Research Registry is a database of adults with non-cystic fibrosis bronchiectasis identified from 13 sites within the United States. Baseline and follow-up demographic, spirometric, microbiologic, and therapeutic data were entered into a central web-based database. Patients were grouped into three cohorts based on their previous respiratory cultures at the time of entry into the Registry: 1) no prior S. aureus or glucose-nonfermenting gram-negative bacilli (NF-GNB) (Pseudomonas, Stenotrophomonas, or Burkholderia spp.); 2) prior S. aureus at least once; or 3) no prior S. aureus but prior NF-GNB at least once. The association between S. aureus isolation and pulmonary function and frequency of exacerbations and hospital admissions was assessed, both at baseline and after 1 year of follow-up.
RESULTS: S. aureus was cultured from 94 of 830 patients (11.3%) included in the analysis. Patients who had grown S. aureus before entry into the Registry had a frequency of prior exacerbations and baseline pulmonary function that was between that of patients who had grown NF-GNB and those who had grown neither NF-GNB or S. aureus. Similarly, at the first follow-up visit after study entry, patients who had grown S. aureus had a frequency of exacerbations and hospitalizations that was between those of patients who had grown NF-GNB and those who had grown neither NF-GNB nor S. aureus. However, in multivariate analysis, S. aureus was not associated with pulmonary function, frequency of exacerbation, or hospital admissions. There were no significant differences in patient characteristics or outcomes between patients who had methicillin-sensitive and methicillin-resistant S. aureus.
CONCLUSIONS: Staphylococcus aureus does not appear to be an independent risk factor for severe disease in patients with bronchiectasis enrolled in the Bronchiectasis Research Registry.

Entities:  

Keywords:  Staphylococcus aureus; bronchiectasis; methicillin-resistant Staphylococcus aureus

Mesh:

Year:  2018        PMID: 29345970      PMCID: PMC5946501          DOI: 10.1513/AnnalsATS.201706-426OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  17 in total

Review 1.  Pathogenesis of bronchiectasis.

Authors:  Bart C Moulton; Alan F Barker
Journal:  Clin Chest Med       Date:  2012-04-06       Impact factor: 2.878

2.  Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?

Authors:  A M Li; S Sonnappa; C Lex; E Wong; A Zacharasiewicz; A Bush; A Jaffe
Journal:  Eur Respir J       Date:  2005-07       Impact factor: 16.671

3.  Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis.

Authors:  P L Shah; S Mawdsley; K Nash; P Cullinan; P J Cole; R Wilson
Journal:  Eur Respir J       Date:  1999-12       Impact factor: 16.671

4.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

Review 5.  A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis.

Authors:  Simon Finch; Melissa J McDonnell; Hani Abo-Leyah; Stefano Aliberti; James D Chalmers
Journal:  Ann Am Thorac Soc       Date:  2015-11

6.  Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.

Authors:  Valerie Waters; Yvonne Yau; Sudha Prasad; Annie Lu; Eshetu Atenafu; Ian Crandall; Stephanie Tom; Elizabeth Tullis; Felix Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2010-10-01       Impact factor: 21.405

7.  Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort.

Authors:  M B Nicotra; M Rivera; A M Dale; R Shepherd; R Carter
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

8.  Microbiologic follow-up study in adult bronchiectasis.

Authors:  Paul T King; Stephen R Holdsworth; Nicholas J Freezer; Elmer Villanueva; Peter W Holmes
Journal:  Respir Med       Date:  2007-04-30       Impact factor: 3.415

9.  Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Authors:  Jonathan Cogen; Julia Emerson; Don B Sanders; Clement Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Pediatr Pulmonol       Date:  2015-06-09

10.  Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients.

Authors:  Heather G Ahlgren; Andrea Benedetti; Jennifer S Landry; Joanie Bernier; Elias Matouk; Danuta Radzioch; Larry C Lands; Simon Rousseau; Dao Nguyen
Journal:  BMC Pulm Med       Date:  2015-06-21       Impact factor: 3.317

View more
  12 in total

1.  Understanding the Role of Staphylococcus aureus in Non-Cystic Fibrosis Bronchiectasis: Where Are We Now?

Authors:  Ranjani Somayaji; Kathleen J Ramos; Lucas R Hoffman
Journal:  Ann Am Thorac Soc       Date:  2018-03

2.  Respiratory Bacterial Microbiota and Individual Bacterial Variability in Lung Cancer and Bronchiectasis Patients.

Authors:  Anuradha Ekanayake; Dushantha Madegedara; Vishvanath Chandrasekharan; Dhammika Magana-Arachchi
Journal:  Indian J Microbiol       Date:  2019-12-11       Impact factor: 2.461

3.  Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.

Authors:  Grant Waterer; John Lord; Thomas Hofmann; Taneli Jouhikainen
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry.

Authors:  Edward Eden; Radmila Choate; Alan Barker; Doreen Addrizzo-Harris; Timothy R Aksamit; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Kevin Fennelly; David E Griffith; Margaret M Johnson; Michael R Knowles; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Gerard M Turino; Kevin L Winthrop
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04-09

5.  Brazilian consensus on non-cystic fibrosis bronchiectasis.

Authors:  Mônica Corso Pereira; Rodrigo Abensur Athanazio; Paulo de Tarso Roth Dalcin; Mara Rúbia Fernandes de Figueiredo; Mauro Gomes; Clarice Guimarães de Freitas; Fernando Ludgren; Ilma Aparecida Paschoal; Samia Zahi Rached; Rosemeri Maurici
Journal:  J Bras Pneumol       Date:  2019-08-12       Impact factor: 2.624

Review 6.  Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis.

Authors:  Sherstin T Lommatzsch
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

7.  Prevalence and Characterization of Coagulase Positive Staphylococci from Food Products and Human Specimens in Egypt.

Authors:  Eman E Abdeen; Walid S Mousa; Sarah Y Abdelsalam; Hanim S Heikal; Reyad R Shawish; Mohammed Nooruzzaman; Mohamed M Soliman; Gaber E Batiha; Ahmed Hamad; Ahmed Abdeen
Journal:  Antibiotics (Basel)       Date:  2021-01-14

8.  Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.

Authors:  Katherine A Despotes; Radmila Choate; Doreen Addrizzo-Harris; Timothy R Aksamit; Alan Barker; Ashwin Basavaraj; Charles L Daley; Edward Eden; Angela DiMango; Kevin Fennelly; Julie Philley; Margaret M Johnson; Pamela J McShane; Mark L Metersky; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Kevin L Winthrop; Michael R Knowles; Mary Leigh Anne Daniels; Peadar G Noone
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

Review 9.  Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics.

Authors:  Kate H Regan; Adam T Hill
Journal:  Curr Pulmonol Rep       Date:  2018-07-05

Review 10.  Antimicrobial Resistance in Common Respiratory Pathogens of Chronic Bronchiectasis Patients: A Literature Review.

Authors:  Riccardo Inchingolo; Chiara Pierandrei; Giuliano Montemurro; Andrea Smargiassi; Franziska Michaela Lohmeyer; Angela Rizzi
Journal:  Antibiotics (Basel)       Date:  2021-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.